top of page

Drive Revenue by Increasing Rx Fulfillment Growth

Writer: Aventria Health GroupAventria Health Group

Pharmaceutical vice presidents, executive directors, brand leads, marketing leads, and commercial leads:

As you mobilize 2025 strategies to drive aggressive brand growth targets, are you challenged with stretch objectives in an environment of intensifying payer impact on the cost of brand access and its negative effect on gross-to-net brand revenue? These include aggressive utilization management techniques demonstrated by stricter PAs, formulary exclusions, shifting cost to members, Rx deductibles, and co-pay maximizers. In addition, the IRA (Inflation Reduction Act) has intensified this challenging access environment on brand revenue by introducing substantial increases in discount/rebate demands and limited price flexibility.

The net effect is frustration with status quo approaches that may not yield needed brand sales results and requests from senior management to identify and implement novel solutions to achieve aggressive brand growth targets.

The collective impact of these marketplace access dynamics is significantly impacting patient out-of-pocket costs, resulting in them forgoing Rx drug therapy or abandoning a drug at the pharmacy dispensing point of service. All brands suffer from unfulfilled prescriptions with Rx rejections and abandonment rates varying by brand. The impact is significant, growing, and negatively affecting brand sales forecasts and revenue.


Patients starting new therapy abandoned 98 million prescriptions at pharmacies in 2023 with increasing frequency as costs rise.1

Co-pays of $75 = abandonment rate of 32%
Co-pays of $250 = abandonment rate of 55%

Rx rejections and abandonment negatively impact all stakeholders:

  • Patients—Despair and dissatisfaction, forgo Rx drug therapy, poorer treatment outcomes

  • Providers—Disruption of patient care plans, prescribing hesitancy, administrative time and cost

  • Manufacturers—Unrealized patient access to drug innovation and reduced brand sales


Using AI in the Switch™ to Help Overcome Lost Prescriptions Due to Rejections and Abandonment

Introducing the EHR Ecosystem AI-enabled software technology platform that engages clinicians and other stakeholders directly in their workflow with specific real-time resources and messages to help overcome lost brand prescriptions with federal anti-kickback compliant support to:

  • Address Rx abandonment and claims rejection with real-time patient benefit profiles

  • Support clinicians with real-time rejection and refill messages by targeting select Rx rejection codes

 

Once patients are identified, the technology helps patients acquire their initial prescription at the Rx dispensing point of service.

Ai identifies claim in switch by NDC code. If rejected, message to HCP based on rejection code

Realize Your Aggressive 2025 Brand Sales Forecast by Increasing Rx Fulfillment—GET 2025 Off to a FAST Start!


Our EHR Ecosystem Platform using AI in the Switch is a proven real-time technology platform that can be configured to help you overcome Rx rejections and abandonment by converting unfulfilled to dispensed Rxs.

 

We have a defined 4-step process to collaboratively work with you to design and implement an EHR Ecosystem switch solution platform unique to your brand challenges.

• Align on goals and success criteria for the solution
•Configure solution as scoped in setup phase
•Distribute based on engagement roadmap and workflow integration
•Analysis od results and optimization of solution/platform

Don’t forget to subscribe to our LinkedIn newsletter Do Well by Doing Good to stay updated with the latest healthcare news, insights, and more.


We welcome an introductory discussion to understand your needs and share how our EHR Ecosystem Platform using AI in the Switch can help you drive brand revenue by overcoming lost prescriptions.

Dave Dierk, Co-President

Dave Dierk, Co-President, 30-year sales and marketing thought leader in pharmaceutical diagnostics, biomedical, long-term care, managed care, employer, and pharmacy communications, at dwdierk@aventriahealth.com.



Paul G. Pochtar, RPh, extensive expertise in leading the successful market access commercialization of both primary care and specialty pharmaceuticals throughout their life cycle, including several landmark oncology products and other specialty therapeutics, at ppochtar@pinnaclehc.com.



Making a difference in patient care by helping patients, providers, and payers collaborate on shared priorities

Comentarios


Aventria follow on linkedin
Contact Us Aventria icon

How Can Aventria Help You Succeed?

Aventria Logo
QC-Health logo

Exclusive reseller

Proud sponsor of

RHV logo
  • LinkedIn
  • email-02

Copyright 2024 Aventria Health Group. All rights reserved.    Privacy Policy

bottom of page